August 11, 2026Journal of the American College of Cardiology235 citationsOpen Access
Transcatheter Mitral Valve Replacement
Key Result
Transcatheter mitral valve replacement demonstrated feasibility as an emerging therapeutic option for severe mitral regurgitation based on early clinical experience in over 100 patients.
Key Points
- This review aims to evaluate the potential of transcatheter mitral valve replacement (TMVR) in treating severe mitral regurgitation.
- Reviewed current TMVR systems under clinical evaluation and their early clinical experiences with over 100 patients.
- Discussed challenges and future perspectives in the field of TMVR.
- TMVR has shown feasibility in initial clinical experiences.
- Early outcomes suggest TMVR may provide better MR reduction compared to transcatheter repair.
Structured PICO
Does transcatheter mitral valve replacement improve outcomes in patients with severe mitral regurgitation at high or prohibitive surgical risk?
P
Population
A review of early clinical experiences evaluating the feasibility of transcatheter mitral valve replacement in over 100 patients with severe mitral regurgitation.
I
Intervention
Transcatheter mitral valve replacement (TMVR)
TMVR is a feasible emerging therapeutic option for severe mitral regurgitation that may provide more complete MR reduction than edge-to-edge repair, though larger studies are needed.
Limitations
- Future studies with a much larger number of patients are needed to provide consistent safety and efficacy data on each of the TMVR systems.
Abstract
Transcatheter mitral valve repair, particularly edge-to-edge leaflet repair, is a well-established alternative for patients with severe primary mitral regurgitation (MR) considered at high or prohibitive surgical risk. More recently, transcatheter mitral valve replacement (TMVR) has emerged as a potential therapeutic option for the treatment of severe MR. TMVR may offer some advantages over transcatheter repair by providing a more complete and reproducible MR reduction. Several devices are under preclinical and clinical evaluation, and the early experience with more than 100 patients has demonstrated the feasibility of TMVR. In this review, we describe the TMVR systems currently in development and the results obtained from early clinical experiences. We also discuss the main challenges in and future perspectives on this emerging field. Future studies with a much larger number of patients are needed to provide consistent safety and efficacy data on each of the TMVR systems.
Expert Takes4 quotes
1/4
“There is no clear indication yet on when to use TMVR for patients with native mitral valve degeneration. Currently, we are using it on patients who are not M-TEER or surgical candidates.”
Samir Kapadia, Chair of Cardiovascular Medicine, Cleveland ClinicCleveland Clinicauto_pipelineView source
Cite This Study
Regueiro et al. (Mon,) conducted a review in Severe mitral regurgitation. Transcatheter mitral valve replacement (TMVR) was evaluated. Transcatheter mitral valve replacement demonstrated feasibility as an emerging therapeutic option for severe mitral regurgitation based on early clinical experience in over 100 patients.